Skip to main content
Download PDF

Impact of CD40 gene polymorphisms on the risk of cervical squamous cell carcinoma: a case-control study

BMC Cancer volume 23, Article number: 845 (2023) Cite this article

Abstract

Background

Cervical cancer is the fourth most common cancer among women worldwide. Genome-wide association studies have revealed multiple susceptible genes and their polymorphisms for cervical cancer risk. Therefore, we aimed to investigate the correlation between single nucleotide polymorphisms (SNPs) of the CD40 gene and susceptibility to cervical squamous cell carcinoma (CSCC) in a population from the northeastern Han Chinese population.

Methods

The three SNPs (rs1800686, rs3765459, and rs4810485) of the CD40 gene were analyzed by multiplex polymerase chain reaction (PCR) combined with next-generation sequencing methods in 421 patients with CSCC, 594 patients with high-grade squamous intraepithelial lesions (HSIL), and 504 healthy females. Multivariate logistic regression analysis was used to analyze the potential relationship between CD40 gene polymorphisms and CSCC, or HSIL.

Results

Our research results showed the AA genotype of rs1800686 had a protective effect on CSCC in comparison to the GG genotype and AG+GG genotypes (AA vs. GG: p = 0.0389 and AA vs. AG+GG: p = 0.0280, respectively). After FDR correction, the results were still statistically significant (p = 0.0389 and p = 0.0389, respectively). Similarly, rs3765459 showed a reduced risk association for CSCC in the codominant and recessive models (AA vs. GG: p = 0.0286 and AA vs. AG+GG: p = 0.0222, respectively). Significant differences remained after FDR correction (p = 0.0286 and p = 0.0286, respectively). However, these differences were no longer significant after the Bonferroni correction. In addition, the genotypes for the rs4810485 polymorphisms were associated with parity of the patients with CSCC. The genotypes for the rs3765459 polymorphisms were significantly correlated with the D-dimer of the patients with CSCC. The 3 SNPs genotypes of the CD40 gene were closely related to the squamous cell carcinoma antigen (SCC) of the patients with HSIL.

Conclusions

The CD40 gene may play a role in the occurrence and development of CSCC.

Peer Review reports

Introduction

Cervical cancer is one of the leading causes of cancer-related deaths in women. In 2020, it is estimated that 604,127 new cervical cancer cases and 341,831 deaths occurred worldwide [1, 2]. However, in China, there are about 109,741 new cases of cervical cancer and 59,060 deaths. China is still one of the countries with the highest incidence and mortality of cervical cancer [3]. There are studies to indicate that risk factors including various sexual partners, early pregnancy, multiple pregnancies within a limited period of time, oral contraceptive pills, smoking habits, and limited access to health care play a role in cervical cancer development [4, 5]. Persistent human papillomavirus (HPV) infection is the most important risk factor for cervical cancer and squamous intraepithelial lesions (SIL) [6, 7]. However, not all patients infected with HPV will develop cervical cancer, and nearly 70–90% of patients can recover from this infection [8]. More importantly, studies revealed that genetic heritability is one of the most common intrinsic factors that increase the probability of developing cervical cancer by almost 27% [9]. According to an Iranian study, cervical cancer susceptibility is closely related to the interaction of HPV infection and host genetic factors. [10].

HPVs are small, non-enveloped, double-stranded DNA viruses and the most common viral culprit of reproductive tract infections, which belong to the Papillomaviridae family [11,12,13]. They are classified into low-risk and high-risk HPVs (lr and hrHPVs) based on their oncogenic capacity [11, 14, 15]. lrHPVs (such as HPV 6, 11, 42, 43, and 44) cause benign epithelial lesions, such as verrucae, warts, and papillomas [14, 16, 17]. while hrHPVs (such as HPV 16, 18, 31, 33, 34, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 70) cause cervical, anal, penile, vulval, vaginal, and oropharyngeal cancer [14, 16, 17]. Infection with hrHPVs, such as the most prevalent HPV 16 and 18 subtypes, results in the constitutive expression of their oncogenes E6 and E7 [18]. E6 and E7 oncogenes can inactivate the functions of the tumor suppressor proteins p53 and retinoblastoma protein and can also inhibit inflammatory responses, in turn suppressing host defense mechanisms against infection and cancer [19,20,21].

CD40 is composed of 277 amino acids and has a molecular weight of 40–50 kDa, which belongs to the tumor necrosis factor receptor (TNFR) superfamily. It is encoded by a gene located on chromosome 20q11–13 and comprises 8 introns and 9 exons [22,23,24]. CD40 is expressed in a variety of cell types, including normal B lymphocytes, macrophages, endothelial cells, and dendritic cells [25]. In addition to being expressed in normal lymphocytes, CD40 is also present in malignant hematopoietic cells, including leukemias, lymphomas, and solid cancers [26]. Some studies have pointed out that CD40 expression is related to the increased risk of angiogenesis in some tumors [27].

Hill SC et al. [28] found that the expression of CD40 on HPV-infected lesions and advanced cervical squamous cell carcinoma (CSCC) is significantly higher than that of normal cervical tissues. These findings were further confirmed by Huang Q et al. [29]. In vivo studies have shown that the expression of CD40 is correlated with HPV positivity, vascular endothelial growth factor (VEGF) expression, and microvessel density [27, 30]. In recent years, various studies have shown that CD40 gene polymorphisms are related to some malignant tumors, such as non-Hodgkin’s lymphoma [31], breast cancer [32], and lung cancer [33, 34]. However, there were few reports on the relationship between the CD40 gene and cervical cancer [35, 36]. Therefore, this study aimed to explore the possible impact of CD40 gene polymorphisms on the occurrence of CSCC and high-grade squamous intraepithelial lesions (HSIL) in the northeastern Han Chinese population.

Materials and methods

Study subjects

The case groups of this case-control study were continuously recruited from the same center (Department of Obstetrics and Gynecology, the Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China) from September 2014 to October 2018. The case groups included 421 patients with CSCC and 594 patients with HSIL. 101 patients with CSCC and 362 patients with HSIL agreed to obtain cervical brushing exfoliated cells to do HR-HPV detection. 92 were found to be HPV positive and 9 were HPV negative in the CSCC patients, and 341 were found to be HPV positive and 21 were HPV negative in the HSIL patients. Further stratification by HPV sub-type shows that 51 samples were HPV 16 and/or 18 in the CSCC patients and 132 samples were HPV 16 and/or 18 in the HSIL patients. All patients were confirmed by pathology experts of the Second Affiliated Hospital of Harbin Medical University. All the women with benign cervical benign lesions, cervical benign tumors, other cervical malignant tumors, and cervical lesions who had a history of preoperative radiotherapy and chemotherapy and other cancers were excluded from the study.

The 504 cases in the control group were all those who went to the physical examination center of the hospital for routine health examinations at the same time. The control group had no history of cancer or family history of cancer, and the results of the Thinprep cytologic test (TCT) were normal. The results of the routine blood examination and other biochemical indicators were within the reference value range. Patients with any gynecological diseases, a history of gynecological diseases, gynecological surgery, hypoimmunity and immunological diseases, skin or genital condyloma, and other cancers were excluded.

All of the cases and controls agreed with the ethics of the study and signed informed consent, which was approved by the ethics committee of the Second Affiliated Hospital of Harbin Medical University.

Selection of SNPs

Based on the characteristics of the East Asian population in the dbSNP database (minor allele frequency [MAF] > 15%) and tracking the relevant literature [35, 36], we selected four SNPs of the CD40 gene. They were rs1800686 (G > A), rs1883832 (T > C), rs3765459 (G > A), and rs4810485 (T > G). Rs1800686 was located in the 508-bp upstream region, rs1883832 was located in the Kozak consensus sequence of the 5´-UTR, rs3765459 was located in the intron 8 of the CD40 gene, and rs4810485 was located in the intron 1 of the CD40 gene.

Extraction and genotyping of DNA

A peripheral venous blood sample (4–5 ml) was collected from each subject into a 2% EDTA-Na2 anticoagulant tube, which was then stored at -80°C until DNA extraction. Genomic DNA from peripheral blood samples was extracted using the TIANamp Genomic DNA Kit supplied by Tiangen Biotech, China. Genotyping of the selected CD40 gene SNPs (rs1800686, rs1883832, rs3765459, and rs4810485) was tested using multiplex PCR combined with next generation sequencing methods by the Shanghai Bio Wing Applied Biotechnology Company (http://www.biowing.com.cn) [37]. Primer3 online software (version 0.4.0, http://frodo.wi.mit.edu/) was used to amplify primer sequences. The primers used for amplification are as follows: for rs1800686 forward 5’-CACTCTTAATAAATGCCTGTCTCC-3’ and reverse 5’-AGAAAACGGGAAGGCCAC-3’; for rs1883832 forward 5’-CCGCGATTGGTCTTTGAAG-3’ and reverse 5’-CTTTCCTTCTCATTCCCCACTC-3’; for rs3765459 forward 5’-CACTCTGGAAGCTCTTCGTC-3’ and reverse 5’-GAAAATTGATCTCCTGGGGTTC-3’ and for rs4810485 forward 5’-CTCATTCTGGAGGCTGGGAATC-3’ and reverse 5’-ATTGCTTCAGGTGAAAGTGAAAG-3’. The TIANgel Midi Purification Kit (Tiangen Biotech, China) was utilized for purifying the PCR products after PCR amplification was performed. The purified PCR products were sequenced on the Illumina HiSeq XTen platform using paired-end sequencing (2 × 150 bp) as directed by the manufacturer. The Burrows-Wheeler Aligner (BWA, v0.7.12) was used to align the sequences to the human reference genome, and the Samtools (v0.1.19) was used for SNP calling and genotyping [38]. Some samples (73 cases) were randomly selected for blind DNA replication for quality control in genotyping.

Statistics

The SPSS software package, version 24.0 (SPSS, Institute Inc.), was used to analyze the clinical characteristics between cases and controls. The genotypic distribution of each SNP in control subjects was tested for departure from Hardy-Weinberg equilibrium (HWE) using an exact test. There were six inheritance models, including the allele model, the codominant model, the dominant model, the recessive model, the overdominant model, and the genotypic model. The 95% confidence interval (CI) and odds ratio (OR) were calculated through multiple logistic regression analysis to evaluate the potential association between CD40 gene polymorphisms and CSCC or HSIL. Empirical p values were calculated by 10,000 permutation tests using the Max (T) permutation procedure implemented in PLINK [39]. We used the false discovery rate (FDR) (p < 0.05 was statistically significant) and the Bonferroni correction (p < 0.016 (0.05/3) was statistically significant) to control for multiple hypothesis testing. SHEsis software was used to implement the Haplotype analysis between groups [40]. For all statistical analyses, p < 0.05 was considered statistically significant.

Results

Quality control and SNP genotype

All of the tested SNPs were in agreement with the HWE in the control population of this study (p > 0.05) except for rs1883832 (p = 0.016), and therefore it was excluded from the analysis (Supplementary Table S1). In addition, quality control was set up for the genotypes of several samples. The genotype calling rate in 73 quality control samples was 98.50%, which fully improved the reliability of the follow-up research results.

Clinical characteristics of the study population

The clinical characteristics of the CSCC group, the HSIL group, and the control group were shown in Table 1. The ages of the patients in the CSCC group and the HSIL group were significantly higher than those in the control group. The ages, menarche ages, fibrinogen (FIB), D-dimer, and squamous cell carcinoma antigen (SCC) of the patients with CSCC were significantly higher than those with HSIL. While the prothrombin time (PT), activated partial thromboplastin time (APTT), and thrombin time (TT) of the patients with CSCC were significantly lower than those with HSIL. The percentages of smoking and amenorrhea were higher in the CSCC group than those in the HSIL group. In addition, there was a significant difference in parity in the CSCC group compared with the HSIL group.

Table 1 Clinical characteristics of all subjects in this study
Full size table

Genotype and allele association analysis

The genotype and allele frequencies of each SNP in the control group and the CSCC group were summarized in Table 2. We found that compared with the control group, rs1800686 was significantly associated with CSCC in the codominant model and the recessive model (AA vs. GG: p = 0.0389 and AA vs. AG + GG: p = 0.0280, respectively). After FDR correction, the results were still statistically significant (p = 0.0389 and p = 0.0389, respectively). There were obvious differences in the genotype frequencies of rs3765459 between the CSCC group and the control group in the codominant model and the recessive model (AA vs. GG: p = 0.0286 and AA vs. AG + GG: p = 0.0222, respectively). Significant differences remained after FDR correction (p = 0.0286 and p = 0.0286, respectively). After 10,000 permutations, the results were still statistically significant (p < 0.05, all). The consistency of 10,000 permutations further supports the reliability of our results. However, these associations did not survive the Bonferroni correction.

Table 2 Distribution of 3 SNPs genotypes and alleles of the CD40 gene in patients with CSCC and controls
Full size table

Further stratification by HPV status showed the CD40 gene SNPs (rs1800686, rs3765459, and rs4810485) were not associated with the risk of HPV infection status (HPV positive, HPV 16 and/or 18, and HPV negative) in the patients with CSCC when compared to controls. Similarly, there were also no significant correlations between the CD40 gene SNPs and the risk of HPV infection status in the patients with HSIL, as shown in Table 3 (p > 0.05, all).

Table 3 Association of CD40 gene SNPs (rs1800686, rs3765459, and rs4810485) with case-control status
Full size table

The genotype and allele frequencies of each SNP in the control group and the HSIL group were summarized in Supplementary Table S2. The results showed that the genotype and allele frequencies of rs1800686, rs3765459, and rs4810485 were not significantly different in the HSIL group compared with the control group (p > 0.05, all). After 10,000 permutations, the results were still not statistically significant (p > 0.05, all).

The genotype and allele frequencies of each SNP in the HSIL group and the CSCC group were analyzed, as shown in Supplementary Table S3. No differences for alleles and genotypes were identified for the comparison of three SNPs (rs1800686, rs3765459, and rs4810485) between the CSCC group and the HSIL group. (p > 0.05, all). After 10,000 permutations, there were still no obvious correlation (p > 0.05, all).

The 3 SNPs genotypes of the CD40 gene in patients with CSCC and HSIL by clinical features were summarized in Table 4. We found that in the CSCC group, the genotypes for the rs4810485 polymorphisms were associated with parity (p = 0.0378), and the genotypes for the rs3765459 polymorphisms were significantly correlated with D-dimer (p = 0.0346). The genotypes for the rs1800686, rs3765459, and rs4810485 polymorphisms were closely related to SCC in the HSIL group (p = 0.0280, p = 0.0199, and p = 0.0042, respectively).

Table 4 Analysis of 3 SNPs genotypes of the CD40 gene in patients with CSCC and HSIL by clinical features
Full size table

Tables 5 and 6 summarized the genotypic associations of three SNPs with risk factors related to CSCC and HSIL, respectively. For rs4810485 in the CSCC group, the parity between patients with the T allele and the G allele was different (p = 0.0138), and the parity between patients with the TT + TG genotype and the GG genotype was different (p = 0.0338). For rs3765459 in the CSCC group, the D-dimer between patients with the AA genotype and the AG + GG genotype was different (p = 0.0326). In the HSIL group, rs4810485 was significantly associated with parity in the dominant model and the genotypic model (p = 0.0237 and p = 0.0417, respectively). The 3 SNPs genotypes of the CD40 gene were significantly correlated with SCC in the HSIL group, and the allele, codominant, dominant, and genotypic models confirmed the credibility of that conclusion, respectively (p < 0.05, all).

Table 5 Genetypic association between 3 SNPs and CSCC-related risk factors
Full size table
Table 6 Genetypic association between 3 SNPs and HSIL-related risk factors
Full size table

Haplotype analysis

Considering the linkage disequilibrium of genes, haplotype analysis for CD40 gene polymorphisms was performed (Supplementary Table S4). Results showed that there were no significant differences between the CSCC group and the control group, the HSIL group and the control group, and the CSCC group and the HSIL group, respectively (p > 0.05, all).

Discussion

The incidence rate of cervical cancer has been kept high in China. The morbidity age has shown a younger trend in recent years. Cervical cancer susceptibility is closely linked to host genetic factors. As a host genetic factor, genetic variation at susceptibility loci may have a significant impact on the risk of cervical cancer [41]. Previous studies on CD40 gene polymorphisms and cervical cancer have been very limited. The association of CD40 gene polymorphisms with the risk of CSCC development in the northeastern Han Chinese population was first investigated in our study. With further study of the CD40 gene, it may be a useful biomarker for evaluating the risk of developing cervical cancer and may also be used as a target for therapy.

These two roles of CD40—promoting immune responses and angiogenesis—have opposing effects on the development of a tumor. Immune responses that are tailored to the tumor prevent tumor growth, whereas enhanced angiogenesis promotes tumor growth by giving the tumor cells nutrition and a path to distant organs [42]. Cervical cancer is more dependent on angiogenesis than other cancers [43]. Angiogenesis, the development of new blood vessels, is essential for the initiation of tumors, their growth, and metastasis [44]. The process of tumor-related angiogenesis is regulated by various pro-angiogenic factors, such as VEGF and interleukin 6 (IL-6), which are the dominant regulators of the proliferation of endothelial cells and the formation of new blood vessels [45, 46]. The activation of CD40 can upregulate VEGF, IL-6, and other factors through MAPK, PI3K/Akt, and other signal transduction pathways and then promote tumor angiogenesis by inhibiting endothelial cell apoptosis and promoting the growth of vascular endothelial cells, so as to promote the occurrence and development of cervical cancer [44, 47, 48]. Zhang et al. [49] reported that some SNPs in the coding region can change the amino acid sequence of proteins, while some SNPs in the non-coding region may still affect gene splicing, transcription factor binding, messenger RNA degradation, or the sequence of non-coding RNA. CD40 gene SNPs can affect the transcription and translation efficiency of CD40, which can determine the effective expression of CD40.

In this study, we investigated the potential effects of rs1800686, rs3765459, and rs4810485 polymorphisms on the occurrence of CSCC and HSIL. Our results showed that rs1800686 and rs3765459 were associated with the risk of CSCC. To date, no study has discussed the association of the rs1800686, rs3765459, and rs4810485 polymorphisms with CSCC risk. Rs1800686 and rs3765459 may be closely related to the pathological classification of cervical cancer. The AA genotype of rs1800686 had a protective effect on CSCC in comparison to the AG + GG genotypes in the recessive model, and these data were statistically significant (CSCC vs. control: OR = 0.552, 95% CI = 0.325–0.938, p = 0.0280). Similarly, rs3765459 showed a reduced risk association for CSCC in the recessive model (CSCC vs. control: OR = 0.527, 95% CI = 0.304–0.912, p = 0.022). The same results appeared in the codominant model (AA vs. GG). Even after 10,000 permutations and FDR correction, the associations held (p < 0.05). Although the interaction effect was not significant after Bonferroni correction, it also suggested a high potential interaction effect as Bonferroni correction was a conservative and stringent correction test. Studies in larger patient cohorts would contribute to elucidating this interaction. Rs1800686 is located in the 5’ near-gene region of the CD40 gene, where mutations can modulate CD40 promoter activity. Rs3765459 is located in intron 8 of the CD40 gene, where mutations can lead to abnormal splicing. Therefore, the AA genotypes of rs1800686 and rs3765459 may inhibit CD40 expression. The decrease in CD40 expression levels can down-regulate VEGF, IL-6, and other factors, reducing the risk of CSCC by promoting endothelial cell apoptosis, inhibiting the growth of vascular endothelial cells, and inhibiting tumor angiogenesis. Shuang et al. [32] demonstrated that the rs1800686 and rs3765459 AA genotypes may increase the risk of breast cancer. They observed that the rs1800686 and rs3765459 AA genotypes were higher in patients with breast cancer compared with the control group. A possible explanation for the inconsistencies between the rs1800686 and rs3765459 polymorphisms and different types of cancer is that these polymorphisms might have different genetic effects on different diseases. Similar results can be seen in the studies of Chen et al. [50] and Yi et al. [51], in which they found that the impacts of genetic polymorphisms may be different according to the types of cancer.

Yan et al. [36] reported the association between CD40 gene polymorphisms and cervical cancer in the Yunnan Han population, pointing out that there was no significant association between rs4810485 and cervical cancer. Purushotham Krishnappa et al. [35] pointed out that rs1800686 and rs4810485 were not related to the occurrence of cervical cancer in the Malaysian population; however, for rs3765459, the G allele increased the risk of cervical cancer (p = 0.010). In our study, we discovered no significant associations between the three SNPs of the CD40 gene and the risk of HSIL. The same results appeared in the comparison of CSCC and HSIL women. The reasons for these negative results remain unknown, but two possibilities should be considered. First, it may be because of genetic trait differences; as we know, genetic polymorphisms in human genes are distinct in different ethnicities, populations, and geographic regions. In addition, even though we might find a potential link between the disease-causing gene and the disease itself, cervical cancer is a multi-factorial disease, and individual exposure to diverse environmental factors and genetic backgrounds may cause different results.

Rs4810485 had no significant correlation with the genetic susceptibility of CSCC (p > 0.05). However, in the CSCC group, the genotypes for the rs4810485 polymorphisms were associated with parity. The genotypes for the rs3765459 polymorphisms were significantly correlated with the D-dimer of the patients with CSCC. The 3 SNPs genotypes of the CD40 gene were significantly correlated with the SCC of the patients with HSIL, suggesting that the CD40 gene polymorphisms genotypes may affect the level of SCC in the patients with HSIL, and further researches are needed.

Studies conducted in vivo and in vitro found that, in contrast to healthy cervical epithelium and non-cancerous keratinocyte cell lines transfected with HPV-DNA, oncogenic HPV positive cervical cancer and HPV-positive cervical cancer cell lines expressed CD40 at high levels [28, 52]. This disparity may explain why HPV infection persists by evading the immune system. The reason cervical cancer has a bad prognosis when the HPV-18 genotype is present may be due to this immune evasion [53]. Unfortunately, we did not find an interaction between the CD40 gene SNPs (rs1800686, rs3765459, and rs4810485) and the risk of HPV infection status (HPV positive, HPV 16 and/or 18, and HPV negative) in CSCC patients; more samples are required in future studies.

Since CD40 gene polymorphisms may correlate with CSCC susceptibility, it is convinced that clarification of how polymorphisms of the CD40 gene have affected mRNA expression and protein expression and how the protein performs in the pathogenesis of the disease is meaningful and helpful. It is widely accepted that mRNA may be regulated by SNPs [54]. Therefore, the mutation of the CD40 gene may affect the expression of CD40 and play an anti-tumor role. In our study, we did not discuss the association between these polymorphisms and CD40 expression in CSCC and HSIL. Functional studies in the future are necessary to elucidate how polymorphisms regulate CD40 expression, especially their role in cervical cancer pathogenesis.

There were some limitations in the present study. First of all, we found the CD40 gene SNPs (rs1800686, rs3765459, and rs4810485) with specific HPV genotypes did not influence the patients’ susceptibility towards the developments of HSIL or CSCC; however, the conclusion is to proceed with caution because only 463 patients (45.6%) underwent HR-HPV detection. Second, the association between CD40 gene polymorphism and its expression level was not investigated, which many previous reports have confirmed. Third, cervical cancer is a complex disease affected by multiple genes, but we only studied the limited sites of the CD40 gene, and other functional genes and SNPs have not been explored. Therefore, the role of CD40 and other genes in the occurrence and development of cervical cancer remains to be further studied.

Conclusion

In conclusion, the study presented is the first to analyze the CD40 gene polymorphisms in a northeastern Han Chinese population with CSCC and HSIL, which revealed that rs1800686 and rs3765459 were significantly associated with the decreased risk of CSCC. In addition, the genotypes for the rs4810485 polymorphisms were associated with parity of the patients with CSCC. The genotypes for the rs3765459 polymorphisms were significantly correlated with the D-dimer of the patients with CSCC. The 3 SNPs genotypes of the CD40 gene were closely related to the SCC of the patients with HSIL. Despite the fact that interactions became insignificant after Bonferroni correction, these findings provide novel evidence for risk assessment and personalized intervention in Chinese women with CSCC.

Data Availability

The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.

Data Availability

SNP date is available in the Figshare database (https://figshare.com/), https://doi.org/10.6084/m9.figshare.19687518.v1.

References

  1. Das M. WHO launches strategy to accelerate elimination of cervical cancer[J]. Lancet Oncol. 2021;22(1):20–1. https://doi.org/10.1016/S1470-2045(20)30729-4.

    Article  PubMed  Google Scholar 

  2. Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 Countries[J]. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

    Article  PubMed  Google Scholar 

  3. Cao W, Chen HD, Yu YW, et al. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020[J]. Chin Med J (Engl). 2021;134(7):783–91. https://doi.org/10.1097/CM9.0000000000001474.

    Article  PubMed  Google Scholar 

  4. Danolic D, Heffer M, Wagner J, et al. Role of ganglioside biosynthesis genetic polymorphism in cervical cancer development[J]. J Obstet Gynaecol. 2020;40(8):1127–32. https://doi.org/10.1080/01443615.2019.1692801.

    Article  CAS  PubMed  Google Scholar 

  5. Ginsburg O, Horton R. A Lancet Commission on women and cancer[J]. Lancet. 2020;396(10243):11–3. https://doi.org/10.1016/S0140-6736(20)31479-3.

    Article  PubMed  Google Scholar 

  6. Li J, Gao JJ, Li N, et al. Distribution of human papillomavirus genotypes in western China and their association with cervical cancer and precancerous lesions[J]. Arch Virol. 2021;166(3):853–62. https://doi.org/10.1007/s00705-021-04960-z.

    Article  CAS  PubMed  Google Scholar 

  7. Xu H, Zhang J. [Interpretation of updated pathological contents for cervical cancer in NCCN clinical practice guidelines, version 1, 2020][J]. Zhonghua Bing Li Xue Za Zhi. 2021;50(1):9–13. https://doi.org/10.3760/cma.j.cn112151-20200712-00548.

    Article  CAS  PubMed  Google Scholar 

  8. Nahand JS, Taghizadeh-Boroujeni S, Karimzadeh M, Borran S, Pourhanifeh MH, Moghoofei M, et al. microRNAs: New prognostic, diagnostic, and therapeutic biomarkers in cervical cancer. J Cell Physiol. 2019;234:17064–99.

    Article  CAS  PubMed  Google Scholar 

  9. Magnusson PK, Lichtenstein P, Gyllensten UB. Heritability of cervical tumours. Int J Cancer. 2000;88:698–701.

    Article  CAS  PubMed  Google Scholar 

  10. Bahrami A, Hasanzadeh M, Shahidsales S, et al. Genetic susceptibility in cervical cancer: from bench to bedside[J]. J Cell Physiol. 2018;233(3):1929–39. https://doi.org/10.1002/jcp.26019.

    Article  CAS  PubMed  Google Scholar 

  11. Jendoubi-Ferchichi M, Satouri L, Ghoul F, Malek-Mellouli M, Derbel AM, Makni MK, et al. Phylogeny and classification of human papillomavirus (HPV)16 and HPV18 variants based on E6 and L1 genes in tunisian women with cervical lesions. Asian Pac J Cancer Prev. 2018;19(12):3361–6. https://doi.org/10.31557/APJCP.2018.19.12.3361.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Graham SV. Human papillomavirus: gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies. Future Microbiol. 2010;5(10):1493–506. https://doi.org/10.2217/fmb.10.107.

    Article  CAS  PubMed  Google Scholar 

  13. Horvath CA, Boulet GA, Renoux VM, Delvenne PO, Bogers JP. Mechanisms of cell entry by human papillomaviruses: an overview. Virol J. 2010;7:11. https://doi.org/10.1186/1743-422X-7-11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev. 2003;16(1):1–17. https://doi.org/10.1128/CMR.16.1.1-17.2003.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Bletsa G, Zagouri F, Amoutzias GD, Nikolaidis M, Zografos E, Markoulatos P, et al. Genetic variability of the HPV16 early genes and LCR. Present and future perspectives. Expert Rev Mol Med. 2021;23:e19. https://doi.org/10.1017/erm.2021.18.

    Article  CAS  PubMed  Google Scholar 

  16. Ault KA. Human papillomavirus vaccines and the potential for cross-protection between related HPV types. Gynecol Oncol. 2007;107(2 Suppl 1). https://doi.org/10.1016/j.ygyno.2007.08.059. S31-3.

  17. Wang LN, Wang L, Cheng G, Dai M, Yu Y, Teng G, et al. The association of telomere maintenance and TERT expression with susceptibility to human papillomavirus infection in cervical epithelium. Cell Mol Life Sci. 2022;79(2):110. https://doi.org/10.1007/s00018-021-04113-0.

    Article  CAS  PubMed  Google Scholar 

  18. Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382(9895):889–99. https://doi.org/10.1016/S0140-6736(13)60022-7.

    Article  PubMed  Google Scholar 

  19. Takeuchi F, Kukimoto I, Li Z, Li S, Li N, Hu Z, et al. Genome-wide association study of cervical cancer suggests a role for ARRDC3 gene in human papillomavirus infection. Hum Mol Genet. 2019;28(2):341–8. https://doi.org/10.1093/hmg/ddy390.

    Article  CAS  PubMed  Google Scholar 

  20. Chen D, Cui T, Ek WE, Liu H, Wang H, Gyllensten U. Analysis of the genetic architecture of susceptibility to cervical cancer indicates that common SNPs explain a large proportion of the heritability. Carcinogenesis. 2015;36(9):992–8. https://doi.org/10.1093/carcin/bgv083.

    Article  CAS  PubMed  Google Scholar 

  21. Pett M, Coleman N. Integration of high-risk human papillomavirus: a key event in cervical carcinogenesis. J Pathol. 2007;212(4):356–67. https://doi.org/10.1002/path.2192.

    Article  CAS  PubMed  Google Scholar 

  22. Morio T, Hanissian S, Geha RS. Characterization of a 23-kDa protein associated with CD40[J]. Proc Natl Acad Sci U S A. 1995;92(25):11633–6. https://doi.org/10.1073/pnas.92.25.11633.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Quezada SA, Jarvinen LZ, Lind EF, et al. CD40/CD154 interactions at the interface of tolerance and immunity[J]. Annu Rev Immunol. 2004;22:307–28. https://doi.org/10.1146/annurev.immunol.22.012703.104533.

    Article  CAS  PubMed  Google Scholar 

  24. AbdelGhafar MT, El-Kholy RA, Elbedewy TA, et al. Impact of CD40 gene polymorphisms on the risk of immune thrombocytopenic purpura[J]. Gene. 2020;736:144419. https://doi.org/10.1016/j.gene.2020.144419.

    Article  CAS  PubMed  Google Scholar 

  25. Zhang Y, Wang N, Ding M, et al. CD40 accelerates the Antigen-Specific Stem-Like Memory CD8(+) T cells formation and human papilloma virus (HPV)-Positive tumor Eradication[J]. Front Immunol. 2020;11:1012. https://doi.org/10.3389/fimmu.2020.01012.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Vonderheide RH. Prospect of targeting the CD40 pathway for cancer therapy. Clin Cancer Res. 2007;13:1083–8. https://doi.org/10.1158/1078-0432.CCR-06-1893.

    Article  CAS  PubMed  Google Scholar 

  27. Huang Q, Qu QX, Xie F, et al. CD40 is overexpressed by HPV16/18-E6 positive cervical carcinoma and correlated with clinical parameters and vascular density[J]. Cancer Epidemiol. 2011;35(4):388–92. https://doi.org/10.1016/j.canep.2010.12.004.

    Article  CAS  PubMed  Google Scholar 

  28. Seran CH, Sarah JY, Stephen M, Glyn RT, Amanda JB, Andrew H, et al. Activation of CD40 in cervical carcinoma cells facilitates CTL responses and augments chemotherapy-induced apoptosis. J Immunol (Baltimore Md : 1950). 2005;174(1):41–50. https://doi.org/10.4049/jimmunol.174.1.41.

    Article  Google Scholar 

  29. Huang Q, Qu QX, Xie F, Hu JM, Chen YG, Zhang XG. Sensitization of SiHa cell to gemcitabine by CD40 activation and its overexpression in cervical carcinoma. Med Oncol. 2011;28:781–8.

    Article  CAS  PubMed  Google Scholar 

  30. Altenburg A, Abdel-Naser MB, Nikolakis G, et al. CD40/CD40 ligand interactions and TNFα treatment reduce activity of P105 promoter of the human papilloma virus-18 in vitro[J]. Exp Oncol. 2016;38(1):22–5.

    Article  CAS  PubMed  Google Scholar 

  31. Nieters A, Bracci PM, de Sanjosé S, et al. A functional TNFRSF5 polymorphism and risk of non-hodgkin lymphoma, a pooled analysis[J]. Int J Cancer. 2011;128(6):1481–5. https://doi.org/10.1002/ijc.25420.

    Article  CAS  PubMed  Google Scholar 

  32. Shuang C, Dalin L, Weiguang Y, Zhenkun F, Fengyan X, Da P, et al. Association of CD40 gene polymorphisms with sporadic breast cancer in chinese Han women of Northeast China. PLoS ONE. 2011;6:e23762. https://doi.org/10.1371/journal.pone.0023762.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. Zhou G, Wang Y, Fang Z, et al. CD40 -1 C > T polymorphism and the risk of lung cancer in a chinese population[J]. Int J Clin Exp Pathol. 2015;8(11):15163–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  34. Tang W, Xue L, Yan Q, Cai S, Bai Y, Lin L, et al. Association of single nucleotide polymorphisms in the apoptosis-related genes TP63 and CD40 with risk for Lung Cancer in a chinese Han Population. Tohoku J Exp Med. 2016;238:279–86. https://doi.org/10.1620/tjem.238.279.

    Article  CAS  PubMed  Google Scholar 

  35. Krishnappa P, Kong HM, Mohamad IB, Voon K, Somanath SD. CD40 polymorphism in cervical carcinoma in a subset of malaysian population. J Obstet Gynaecol Res. 2017;43:923–8.

    Article  CAS  PubMed  Google Scholar 

  36. Yan ZL, Yang XL, Zhang HP, Yin CM, Zhang S, Li WL, Li HY. Association of polymorphisms in CD40 gene with cervical cancer in chinese Han population in Yunnan province. Chin J Cancer Prev Treat. 2017;24:1331–4.

    CAS  Google Scholar 

  37. Chen K, Zhou YX, Li K, et al. A novel three-round multiplex PCR for SNP genotyping with next generation sequencing[J]. Anal Bioanal Chem. 2016;408(16):4371–7. https://doi.org/10.1007/s00216-016-9536-6.

    Article  CAS  PubMed  Google Scholar 

  38. Li H. A statistical framework for SNP calling, mutation discovery, association mapping and population genetical parameter estimation from sequencing data. Bioinformatics. 2011;27:2987–93. https://doi.org/10.1093/bioinformatics/btr509.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet. 2007;81(3):559–75. https://doi.org/10.1086/519795.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  40. Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 2005;15:97–8. https://doi.org/10.1038/sj.cr.7290272.

    Article  CAS  PubMed  Google Scholar 

  41. Bahrami A, Hasanzadeh M, ShahidSales S, Yousefi Z, Kadkhodayan S, Farazestanian M, et al. Clinical significance and prognosis value of wnt signaling pathway in Cervical Cancer. J Cell Biochem. 2017;118:3028–33. https://doi.org/10.1002/jcb.25992.

    Article  CAS  PubMed  Google Scholar 

  42. Bergmann S, Pandolfi PP. Giving blood: a new role for CD40 in tumorigenesis. J Exp Med. 2006;203:2409–12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Monk BJ, Sill MW, McMeekin DS, Cohn DE, Ramondetta LM, Boardman CH, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic Oncology Group study. J Clin Oncol. 2009;27:4649–55. https://doi.org/10.1200/JCO.2009.21.8909.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Chuai Y, Rizzuto I, Zhang X, Li Y, Dai G, Otter SJ, et al. Vascular endothelial growth factor (VEGF) targeting therapy for persistent, recurrent, or metastatic cervical cancer. Cochrane Database Syst Rev. 2021;3:CD013348.

    PubMed  Google Scholar 

  45. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, et al. Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res. 1992;52:3317–22.

    CAS  PubMed  Google Scholar 

  46. Tan A, Xia N, Gao F, Mo Z, Cao Y. Angiogenesis-inhibitors for metastatic thyroid cancer. Cochrane Database Syst Rev. 2010;2010:CD007958.

    PubMed  PubMed Central  Google Scholar 

  47. Flaxenburg JA, Melter M, Lapchak PH, Briscoe DM, Pal S. The CD40-induced signaling pathway in endothelial cells resulting in the overexpression of vascular endothelial growth factor involves ras and phosphatidylinositol 3-kinase. J Immunol. 2004;172:7503–9. https://doi.org/10.4049/jimmunol.172.12.7503.

    Article  CAS  PubMed  Google Scholar 

  48. Zirlik A, Bavendiek U, Libby P, MacFarlane L, Gerdes N, Jagielska J, et al. TRAF-1, -2, -3, -5, and – 6 are induced in atherosclerotic plaques and differentially mediate proinflammatory functions of CD40L in endothelial cells. Arterioscler Thromb Vasc Biol. 2007;27:1101–7. https://doi.org/10.1161/ATVBAHA.107.140566.

    Article  CAS  PubMed  Google Scholar 

  49. Zhang B, Wu T, Song C, Chen M, Li H, Guo R. Association of CD40–1 C/T polymorphism with cerebral infarction susceptibility and its effect on sCD40L in chinese population. Int Immunopharmacol. 2013;16:461–5. https://doi.org/10.1016/j.intimp.2013.04.028.

    Article  CAS  PubMed  Google Scholar 

  50. Chen P, Sun R, Pu Y, Bai P, Yuan F, Liang Y, et al. Pri-Mir-34b/C and Tp-53 polymorphisms are Associated with the susceptibility of papillary thyroid carcinoma: a case-control study. Med (Baltim). 2015;94:e1536.

    Article  CAS  Google Scholar 

  51. Yi DH, Wang BG, Zhong XP, Liu H, Liu YF. Pri-miR-34b/c rs4938723 TC heterozygote is associated with increased cancer risks: evidence from published data. Tumour Biol. 2014;35:11967–75.

    Article  CAS  PubMed  Google Scholar 

  52. S E B AA. H S, H P, S H. CD40 ligand-CD40 interaction induces chemokines in cervical carcinoma cells in synergism with IFN-gamma. Journal of immunology (Baltimore, Md.: 1950). 1999;162(7):4140-7.

  53. Angiolo G, Maria Elena G, Carlo G. Tissue biomarkers as prognostic variables of cervical cancer. Crit Rev Oncol Hematol. 2013;86(2):104–29. https://doi.org/10.1016/j.critrevonc.2012.09.003.

    Article  Google Scholar 

  54. Lu YF, Mauger DM, Goldstein DB, Urban TJ, Weeks KM, Bradrick SS. IFNL3 mRNA structure is remodeled by a functional non-coding polymorphism associated with hepatitis C virus clearance. Sci Rep. 2015;5:16037.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank all participants in the study.

Funding

This study was supported by the National Natural Science Foundation of China (No. 82071929).

Author information

Authors and Affiliations

  1. Cancer Center, Department of Ultrasound Medicine, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital), Hangzhou Medical College, Hangzhou, Zhejiang, China

    Manning Zhu, Xiaoying Li, Tianshuang Jia, Songxue Li, Liping Gong, Shuang Dong & Litao Sun

  2. Department of Ultrasound, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China

    Yanan Feng

  3. Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang Province, China

    Xianchao Kong

Authors
  1. Manning Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Xiaoying Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yanan Feng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tianshuang Jia
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Songxue Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liping Gong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shuang Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Xianchao Kong
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Litao Sun
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Manning Zhu: data collection, data analysis, and drafting the manuscript. Xiaoying Li and Yanan Feng: data analysis and revision of the manuscript. Tianshuang Jia and Songxue Li: data collection and data analysis. Liping Gong and Shuang Dong: patient screening. Xianchao Kong: data analysis. Litao Sun: experimental design and overall planning. All authors contributed to the article and approved of the final version for publication.

Corresponding author

Correspondence to Litao Sun.

Ethics declarations

Competing interests

The authors declare no competing interests.

Ethics approval and consent to participate

The study protocol was approved by the ethics committee of the Second Affiliated Hospital of Harbin Medical University and was performed in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained from all the study subjects before enrollment.

Consent for publication

Not applicable.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Zhu, M., Li, X., Feng, Y. et al. Impact of CD40 gene polymorphisms on the risk of cervical squamous cell carcinoma: a case-control study. BMC Cancer 23, 845 (2023). https://doi.org/10.1186/s12885-023-11367-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12885-023-11367-3

Keywords

BMC Cancer

ISSN: 1471-2407

Contact us